Natural killer cells have an activated profile in early Parkinson's disease.
Immune system
Natural killer cells
Parkinson's disease
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
19
04
2023
revised:
04
07
2023
accepted:
23
07
2023
medline:
18
9
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Immune dysregulation is heavily implicated in Parkinson's disease (PD) but the role of Natural Killer (NK) cells has not been well characterised. Accumulating evidence indicates the immune response peaks early in the disease, hence this study focused on characterising NK cells in recently diagnosed PD. PBMCs were obtained from PD cases (< 2 years duration) and age-matched controls and immunophenotyped using flow cytometry. We found an increased proportion and number of NK cells (CD3-CD56+), mature cytotoxic NK cells (CD3-CD16 + CD56dim), and NK cells expressing the activation marker, NKG2D. This implies NK cells are activated in the earliest stages of PD.
Identifiants
pubmed: 37549558
pii: S0165-5728(23)00140-6
doi: 10.1016/j.jneuroim.2023.578154
pii:
doi:
Substances chimiques
CD56 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
578154Subventions
Organisme : Medical Research Council
ID : MR/R007446/1
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR203312
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no competing interests relevant to this work.